Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Table 4 Choroidal neovascularization in the fellow eye developing from 0 to 24 months after baseline versus Barbazetto et al. [41]

	Conversions in current study (conversions/fellow eyes with dry AMD)	Conversions-Barbazetto et al. [41] (conversions/fellow eyes with dry AMD)	p-value
TT, 12 months	12/160 (20 %)	100/445 (22.5 %)	0.0001
TTZ, 12 months	3/80 (3.75 %)	100/445 (22.5 %)	0.00003
TT, 24 months	20/160 (12.5 %)	151/445 (33.9 %)	0.0000006
TTZ, 24 months	5/80 (6.25 %)	151/445 (33.9 %)	1 × 1.0⁻¹⁴

TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, CFT central foveolar thickness

ISSN: 2056-9920